Ground Swell Capital LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Ground Swell Capital LLC purchased a new position in shares of Insulet Co. (NASDAQ:PODD) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,343 shares of the medical instruments supplier’s stock, valued at approximately $271,000.

Several other large investors also recently bought and sold shares of the business. Sunbelt Securities Inc. purchased a new stake in shares of Insulet in the first quarter valued at about $29,000. International Assets Investment Management LLC acquired a new stake in shares of Insulet during the 2nd quarter worth about $32,000. Benjamin F. Edwards & Company Inc. purchased a new stake in Insulet in the 4th quarter valued at about $34,000. UMB Bank n.a. lifted its position in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the last quarter. Finally, Jones Financial Companies Lllp purchased a new position in Insulet during the fourth quarter worth about $40,000.

Insider Transactions at Insulet

In related news, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the completion of the transaction, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Up 3.4 %

PODD opened at $226.50 on Wednesday. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $227.26. The stock has a market capitalization of $15.86 billion, a P/E ratio of 68.64, a P/E/G ratio of 4.02 and a beta of 1.21. The business has a 50 day simple moving average of $197.19 and a 200-day simple moving average of $184.66.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. During the same period last year, the company earned $0.38 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, equities analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PODD shares. Canaccord Genuity Group restated a “buy” rating and set a $234.00 target price on shares of Insulet in a report on Tuesday, July 23rd. OTR Global restated a “mixed” rating on shares of Insulet in a report on Monday, June 10th. UBS Group upped their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Redburn Atlantic initiated coverage on shares of Insulet in a research report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price target for the company. Finally, Barclays upped their price objective on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $225.29.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.